Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8TC59

UPID:
PIWL2_HUMAN

ALTERNATIVE NAMES:
Cancer/testis antigen 80

ALTERNATIVE UPACC:
Q8TC59; A8K4S3; A8K8S5; B0AZN9; B0AZP2; B4DR22; E7ECA4; Q96SW6; Q9NW28

BACKGROUND:
Piwi-like protein 2, recognized as Cancer/testis antigen 80, is essential for maintaining germline integrity by suppressing transposable elements during spermatogenesis. It supports meiotic differentiation, germ cell differentiation, and the renewal of spermatogonial stem cells, primarily through the piRNA metabolic pathway. This pathway suppresses transposable elements in meiosis by forming piRNA-Piwi protein complexes, leading to transposon methylation. Piwi-like protein 2's role in the piRNA amplification loop is crucial, serving as an endoribonuclease that cleaves primary piRNAs.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Piwi-like protein 2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.